Solid Biosciences LLC Key Fundamental And Technical Indicators
| SLDB Stock | USD 7.27 0.20 2.83% |
Momentum
OversoldOverbought
50 · Neutral
As of the 10th of May, the last recorded price for Solid Biosciences is 7.27 per share. Primary technical drivers reflect Coefficient Of Variation of 1780.16, risk adjusted performance of 0.0625, and Semi Deviation of 4.77. Quantitative analysis incorporates volatility metrics and price behavior to assess directional bias. Metrics are compared to industry averages to assess relative positioning.
Solid Biosciences' financial statements serve as the foundation for evaluating earnings quality and balance sheet strength. Key valuation metrics and long-term strategic positioning are highlighted below: Analyzing Solid Biosciences's margins, turnover ratios, and leverage metrics provides a structured basis for estimation. Core indicators are listed below:Solid Biosciences LLC does not currently have any fundamental trend indicators for analysis. See Equity Screeners for additional filtering and comparison across instruments. The framework supports screening across sectors, industries, and market segments.Solid Biosciences' Return on Equity (ROE) measures how effectively a company converts shareholders' equity into net income. It is calculated by dividing net income by average shareholders' equity, and it reflects management's ability to generate profit from the capital investors have committed. ROE is one of the most widely used profitability ratios because it ties directly to shareholder value creation.
Return On Equity | = | Net IncomeTotal Equity |
Current Solid Biosciences Return On Equity TTM | -1.1 |
Ratios like Return On Equity TTM help investors see if Solid Biosciences' market price truly reflects the company's real worth. Ratios like Return On Equity TTM help measure how much Solid Biosciences' price reflects or strays from intrinsic value estimate.
| Competition |
Solid Biosciences LLC Fundamental Drivers Relationships
Main Technical Indicators as of May 10, 2026
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0625 | |||
| Market Risk Adjusted Performance | 0.1452 | |||
| Mean Deviation | 4.06 | |||
| Semi Deviation | 4.77 | |||
| Downside Deviation | 5.04 | |||
| Coefficient Of Variation | 1780.16 | |||
| Standard Deviation | 5.62 | |||
| Variance | 31.64 | |||
| Information Ratio | 0.0548 | |||
| Jensen Alpha | 0.3108 | |||
| Total Risk Alpha | 0.3185 | |||
| Sortino Ratio | 0.0611 | |||
| Treynor Ratio | 0.1352 | |||
| Maximum Drawdown | 29.04 | |||
| Value At Risk | -8.25 | |||
| Potential Upside | 8.23 | |||
| Downside Variance | 25.42 | |||
| Semi Variance | 22.78 | |||
| Expected Short fall | -4.51 | |||
| Skewness | 0.9829 | |||
| Kurtosis | 2.85 |
Daily Market Strength Indicators
Market strength indicators for Solid Biosciences quantify how the stock responds to shifts in volume and sentiment. These indicators capture shifts in momentum that may precede significant price moves in Solid Biosciences. The Market Facilitation Index measures how efficiently price moves relative to volume — rising MFI with rising volume signals strong trend participation. Monitoring these indicators for Solid Biosciences through complete market cycles reveals recurring patterns.
Basic Forecasting Models
Bollinger Bands applied to Solid Stock price data measure how far Solid has deviated from its recent average relative to its own volatility. This distinction drives the choice of forecasting model applied to Solid Biosciences' price data. On-balance volume for Solid Stock creates a running indicator of buying versus selling pressure in Solid. Price departures from the channel boundary often mean-revert, offering tactical signals for Solid Biosciences'.Solid Biosciences Related Equities
Checking Solid Biosciences against related firms within the Health Care space reveals where the stock stands among peers. Peer review on balance sheet metrics shows how Solid Biosciences' capital structure stacks up against similar firms. Falling behind peers on key ratios may signal headwinds or execution issues worth looking into.
| Risk & Return | Correlation |
Return On Equity TTM Peer Comparison
Peer-based analysis of Solid Biosciences on Return On Equity TTM allows investors to benchmark performance against similar stocks. A favorable Solid Biosciences' Return On Equity TTM compared to competitors can indicate undervaluation or a stronger fundamental position. Outlier Return On Equity TTM values among Solid Biosciences peers often point to structural differences in business models. This analysis benchmarks Solid Biosciences against the most relevant set of comparable stocks.Solid Biosciences is currently under evaluation in return on equity ttm among leading competitors.
Important Fundamentals
| Return On Equity TTM | -1.1 | |||
| Return On Asset TTM | -0.53 | |||
| Current Valuation | 544.84 M | |||
| Shares Outstanding | 98.41 M | |||
| Shares Owned By Insiders | 0.82 % | |||
| Shares Owned By Institutions | 84.28 % | |||
| Number Of Shares Shorted | 9.44 M | |||
| Price To Book TTM | 3.95 X | |||
| Price To Sales TTM | 3.65 X | |||
| Gross Profit TTM | -96.43 M | |||
| EBITDA TTM | -177.57 M | |||
| Net Income TTM | -174.32 M | |||
| Cash And Equivalents TTM | 162.88 M | |||
| Cash Per Share TTM | 1.44 X | |||
| Total Debt TTM | 21.16 M | |||
| Debt To Equity TTM | 0.15 % | |||
| Current Ratio TTM | 7.85 X | |||
| Book Value Per Share TTM | 2.28 X | |||
| Cash Flow From Operations TTM | -156.29 M | |||
| Short Ratio TTM | 8.18 X | |||
| Earnings Per Share | -1.99 X | |||
| Target Price | 17.08 | |||
| Number Of Employees | 121 | |||
| Trailing Beta | 2.47 | |||
| Market Capitalization TTM | 695.78 M | |||
| Total Asset TTM | 232.54 M | |||
| Retained Earnings TTM | -957.77 M | |||
| Working Capital TTM | 171.98 M | |||
| Net Asset | 232.54 M |
Financial Metrics, Fundamentals & Methodology
Solid Biosciences's core fundamentals cover profitability, capital efficiency, and funding structure. Cash-flow trends help test whether reported earnings are being backed by real operating performance. For the latest reporting period, Solid Biosciences reports EPS loss of 1.99, current ratio of 7.85, debt-to-equity of 0.15.
Solid Biosciences LLC data is compiled from periodic company reporting and market reference feeds and standardized for comparability. Financial statement fields are presented under issuer-reported GAAP or IFRS accounting conventions.
Editorial review and methodology oversight provided by: Gabriel Shpitalnik, Member of Macroaxis Editorial Board